NANEXA Share Price Performance
SEK 3.61
1.27 (54.72%)
177.3% overvalued intrinsic discount
SEK 1.30
Fair Value
Price SEK 3.61
daemningen4500 SEK 1.30
Fair ValueSEK 1.30
Share Pricen/a
Nanexa AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
NANEXA Community Narratives
DA
Fair Value
·Fair Value SEK 1.3 177.3% overvalued intrinsic discount
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
Nanexa AB is a Swedish pharmaceutical company that specializes in drug delivery systems. Here's a brief overview of its corporate history, ownership, focus, and potential: Corporate History Nanexa was founded in 2007 and is headquartered in Uppsala, Sweden.Read more
DA
SEK 1.3
177.3% overvalued intrinsic discount
Fair Value
Profit Margin
14.37%
Future PE
27.83x
Price in 2030
SEK 1.72
Trending Discussion
Recently Updated Narratives
DA
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
Fair Value: SEK 1.3 177.3% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nanexa AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 27, 2026
- -0.089
- 75.38%
- -30.24%
- 0.8%
About NANEXA
- Founded
- 2007
- Employees
- 15
- CEO
- WebsiteView website
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
